PLX
Income statement / Annual
Last year (2023), Protalix BioTherapeutics, Inc.'s total revenue was $65.49 M,
an increase of 37.48% from the previous year.
In 2023, Protalix BioTherapeutics, Inc.'s net income was $8.31 M.
See Protalix BioTherapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$65.49 M
|
$47.64 M
|
$38.35 M
|
$62.90 M
|
$54.69 M
|
$34.24 M
|
$19.24 M
|
$9.20 M
|
$4.36 M
|
$15.16 M
|
| Cost of Revenue |
$22.98 M |
$19.59 M |
$16.35 M |
$10.87 M |
$10.90 M |
$9.30 M |
$15.23 M |
$8.40 M |
$730,000.00 |
$9.05 M |
| Gross Profit |
$42.51 M |
$28.05 M |
$22.00 M |
$52.03 M |
$43.80 M |
$24.94 M |
$4.01 M |
$801,000.00 |
$3.63 M |
$6.11 M |
| Gross Profit Ratio |
0.65 |
0.59 |
0.57 |
0.83 |
0.8 |
0.73 |
0.21 |
0.09 |
0.83 |
0.4 |
| Research and Development
Expenses |
$17.09 M
|
$29.35 M
|
$29.73 M
|
$38.17 M
|
$44.62 M
|
$33.33 M
|
$28.83 M
|
$24.61 M
|
$20.03 M
|
$21.65 M
|
| General & Administrative
Expenses |
$0.00
|
-$13.58 M
|
-$4.02 M
|
-$5.09 M
|
-$5.97 M
|
$1.94 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing
Expenses |
$0.00
|
$25.29 M
|
$16.75 M
|
$16.24 M
|
$15.87 M
|
$8.98 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$14.96 M
|
$11.71 M
|
$12.73 M
|
$11.15 M
|
$9.90 M
|
$10.92 M
|
$11.53 M
|
$9.36 M
|
$7.28 M
|
$9.66 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$32.05 M |
$41.06 M |
$42.46 M |
$49.32 M |
$54.52 M |
$44.25 M |
$40.36 M |
$33.96 M |
$27.30 M |
$31.31 M |
| Cost And Expenses |
$55.03 M |
$60.65 M |
$58.81 M |
$60.19 M |
$65.41 M |
$53.55 M |
$55.60 M |
$42.36 M |
$28.03 M |
$40.36 M |
| Interest Income |
$1.29 M |
$1.15 M |
$401,000.00 |
$438,000.00 |
$407,000.00 |
$536,000.00 |
$188,000.00 |
$589,000.00 |
$123,000.00 |
$196,000.00 |
| Interest Expense |
$3.18 M |
$2.53 M |
$7.52 M |
$9.67 M |
$7.97 M |
$7.69 M |
$9.73 M |
$10.67 M |
$3.74 M |
$4.94 M |
| Depreciation &
Amortization |
$1.19 M
|
$1.09 M
|
$1.12 M
|
$1.30 M
|
$1.62 M
|
$1.67 M
|
$1.92 M
|
$1.98 M
|
$2.37 M
|
$3.14 M
|
| EBITDA |
$11.65 M
|
-$10.78 M
|
-$18.94 M
|
$4.45 M
|
-$8.69 M
|
-$17.10 M
|
-$71.80 M
|
-$16.53 M
|
-$21.18 M
|
-$25.42 M
|
| EBITDA Ratio |
0.18 |
-0.23 |
-0.52 |
0.05 |
-0.16 |
-0.55 |
-1.88 |
-3.33 |
-5.4 |
-1.65 |
| Operating Income Ratio
|
0.16
|
-0.27
|
-0.53
|
0.03
|
-0.2
|
-0.56
|
-1.89
|
-3.61
|
-5.42
|
-1.66
|
| Total Other
Income/Expenses Net |
-$1.89 M
|
-$1.38 M
|
-$7.12 M
|
-$9.23 M
|
-$7.56 M
|
-$7.15 M
|
$1.84 M
|
$3.99 M
|
-$3.61 M
|
-$4.74 M
|
| Income Before Tax |
$8.57 M |
-$14.40 M |
-$27.58 M |
-$6.52 M |
-$18.28 M |
-$26.46 M |
-$85.28 M |
-$29.18 M |
-$27.28 M |
-$29.94 M |
| Income Before Tax Ratio
|
0.13
|
-0.3
|
-0.72
|
-0.1
|
-0.33
|
-0.77
|
-4.43
|
-3.17
|
-6.25
|
-1.98
|
| Income Tax Expense |
$254,000.00 |
$530,000.00 |
$6.40 M |
$8.37 M |
$7.97 M |
$536,000.00 |
$7.81 M |
$10.85 M |
-$87.57 M |
-$2.94 M |
| Net Income |
$8.31 M |
-$14.93 M |
-$33.99 M |
-$14.89 M |
-$26.24 M |
-$26.46 M |
-$85.28 M |
-$29.37 M |
$58.04 M |
-$29.94 M |
| Net Income Ratio |
0.13 |
-0.31 |
-0.89 |
-0.24 |
-0.48 |
-0.77 |
-4.43 |
-3.19 |
13.3 |
-1.98 |
| EPS |
0.12 |
-0.31 |
-0.77 |
-0.51 |
-1.77 |
-1.8 |
-6.51 |
-0.29 |
0.61 |
-0.32 |
| EPS Diluted |
0.1 |
-0.31 |
-0.77 |
-0.51 |
-1.77 |
-1.8 |
-6.51 |
-0.29 |
0.61 |
-0.32 |
| Weighted Average Shares
Out |
$67.51 M
|
$48.47 M
|
$44.14 M
|
$29.15 M
|
$14.84 M
|
$14.71 M
|
$13.11 M
|
$101.39 M
|
$94.92 M
|
$92.89 M
|
| Weighted Average Shares
Out Diluted |
$82.42 M
|
$48.47 M
|
$44.14 M
|
$29.15 M
|
$14.84 M
|
$14.71 M
|
$13.11 M
|
$101.39 M
|
$94.92 M
|
$92.89 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
